Clik here to view.
Rivaroxaban Gains FDA Indications For The Treatment And Prevention Of DVT And PE
The FDA today expanded the indication for rivaroxaban (Xarelto, Johnson & Johnson) to include the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and to reduce the risk of...
View ArticleClik here to view.
Apixaban Gains Indication For DVT Prophylaxis After Knee And Hip Replacement...
The FDA has approved a new indication for apixaban (Eliquis), the anticoagulant drug manufactured by Bristol-Myers Squibb and Pfizer. The new indication is for the prophylaxis of deep vein thrombosis...
View ArticleClik here to view.
FDA Grants New Indication For Apixaban
The FDA today approved an expanded indication for the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb and Pfizer). Apixaban will now be indicated for the treatment of deep venous thrombosis...
View ArticleClik here to view.
Economic Study Finds VTE Prophylaxis with Low-Molecular-Weight Heparin Cost...
Critically ill patients in the hospital are at high risk for developing venous thromboembolism (VTE). The 2011 PROTECT trial compared the two most common drug strategies used to prevent VTE —...
View Article
